Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New US Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms

NEW YORK, May 14, 2019 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Company’s major investment company AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM”), a world leader in cannabinoid research and development, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO). The provisional patent application is for a patent on a chewing gum composition comprising cannabinoids and parthenolide (feverfew extract) for treatment of symptoms of migraines.

“As a company of firsts, Medical Marijuana, Inc. is proud to support AXIM as it files this patent application for the first-ever cannabis-based gum formulated to treat the symptoms of migraines,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Studies have estimated that migraines affect roughly 38 million people in the U.S. and the market currently lacks an effective natural

... read more at: https://www.prnewswire.com/news-releases/medical-marijuana-inc-major-investment-company-axim-biotechnologies-files-new-us-provisional-patent-for-cannabis-gum-as-a-treatment-for-migraine-symptoms-300849536.html

Leave a Reply